U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- Retail Sales Surge: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, indicating a potential rebound in consumer spending that could positively impact economic recovery.
- Tech Stock Decline: Information technology stocks fell by 1.3% on Wednesday, reflecting market concerns over the tech sector, which may affect investor confidence and lead to capital outflows.
- High-Risk Stock Surge: High Roller Technologies, Inc. (NYSE:ROLR) shares skyrocketed 289% to $13.64 after announcing a binding Letter of Intent with Crypto.com to launch an event-based prediction markets product in the U.S., demonstrating strong market demand for innovative offerings.
- IPO Impact: Briacell Therapeutics Corp. (NASDAQ:BCTX) priced its $30 million public offering at $5.59 per unit, leading to a 53% drop in its stock price to $5.09, reflecting market sensitivity to financing activities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Announces Pricing of 1.45 Million Shares at $3.25 Each
- Funding Size: BriaCell Therapeutics Corp. announced the offering of 1,449,300 common shares at $3.25 each, expecting gross proceeds of approximately $4.7 million, which will be used for working capital and advancing corporate objectives, indicating the company's active engagement in capital markets.
- Offering Arrangement: The offering is being managed solely by ThinkEquity and is expected to close on June 2, 2026, reflecting the company's strategic planning in financing aligned with market demand.
- Compliance Assurance: The company is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, ensuring that the transaction complies with relevant regulations, which enhances investor confidence in the company's compliance.
- Future Outlook: BriaCell intends to use the proceeds to advance its cancer immunotherapy development, demonstrating the company's commitment to long-term growth and innovation in the biotechnology sector, which may attract more investor interest in its future potential.
See More
BriaCell Reports Promising Phase 2 Data for Breast Cancer Treatment
- Survival Rate Improvement: The Bria-IMT regimen demonstrated a 55% one-year and 27% two-year survival rate in heavily pre-treated metastatic breast cancer patients, indicating significant potential for improving survival, particularly in patients who have failed multiple therapies.
- Clinical Data Validation: At the 2026 ASCO Annual Meeting, BriaCell reported a median overall survival of 16.6 months in Phase 2 studies, with a clinical benefit rate of 62% among patients who had undergone various treatments, underscoring the regimen's efficacy and tolerability.
- Biomarker Insights: Ongoing biomarker analyses from the Phase 3 study further validate potential predictors of anti-cancer response, with DTH-positive patients showing a median survival of 11.9 months, highlighting the importance of biomarkers in predicting treatment effectiveness.
- Quality of Life Enhancement: In the Bria-ABC study, heavily pre-treated patients maintained stable quality of life without significant toxicity, supporting the feasibility of the regimen in clinical settings and suggesting potential for home self-administration.
See More
BriaCell Therapeutics Prices 1.4 Million Share Best-Efforts Offering
- Offering Size: BriaCell Therapeutics announced a best-efforts offering of approximately 1.4 million shares, indicating the company's strategy to raise capital in the market.
- Market Reaction: The specific pricing details of the offering have not been disclosed, which may affect investor confidence in the company's future fundraising capabilities.
- Use of Proceeds: While the use of proceeds has not been detailed, such financing is typically aimed at research and operational expenses, potentially impacting the company's future project timelines.
- Investor Attention: Investors should monitor subsequent market reactions and company announcements to assess the potential impact of this offering on stock price and financial health.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
BriaCell's Immunotherapy Study Receives Positive DSMB Recommendation
- Clinical Trial Progress: BriaCell Therapeutics' Bria-ABC study in metastatic breast cancer has received its sixth consecutive positive recommendation from the independent Data Safety Monitoring Board, indicating no safety concerns and allowing the trial to proceed without modifications.
- FDA Fast Track Designation: Conducted under FDA Fast Track designation, the study underscores the significant unmet medical need in metastatic breast cancer, highlighting the strategic importance of the company's development of novel immunotherapies.
- CEO's Positive Remarks: CEO Dr. William V. Williams described this milestone as 'another step forward,' emphasizing BriaCell's commitment to addressing urgent patient needs and advancing its immunotherapy approach.
- Stock Performance Volatility: BCTX shares have traded between $2.98 and $36.90 over the past year, closing at $3.49, down 6.18% from the previous trading day, reflecting market caution regarding the company's future prospects.
See More
BriaCell's Phase 3 Study Receives Sixth Positive DSMB Recommendation
- Safety Assessment Results: The independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of BriaCell's Phase 3 Bria-ABC study, indicating favorable safety and tolerability of the immunotherapy, which enhances investor confidence in the company's future prospects.
- FDA Fast Track Designation: The study is being conducted under the FDA's Fast Track designation, reflecting a significant unmet medical need in metastatic breast cancer, positioning BriaCell's innovative therapies to potentially fill this market gap and enhance the company's competitiveness in the biotechnology sector.
- Clinical Trial Progress: The positive DSMB recommendation suggests that the combination of Bria-IMT and immune checkpoint inhibitors shows good safety in clinical trials, potentially offering new hope for patients in urgent need of treatment, thereby increasing BriaCell's market recognition.
- Strategic Company Implications: BriaCell's CEO, William V. Williams, noted that this milestone not only recognizes the company's research capabilities but also lays the groundwork for future financing and collaboration opportunities, further driving innovation in cancer treatment.
See More
BriaCell Announces Pricing of 1.45 Million Shares at $3.25 Each
- Funding Size: BriaCell Therapeutics Corp. announced the offering of 1,449,300 common shares at $3.25 each, expecting gross proceeds of approximately $4.7 million, which will be used for working capital and advancing corporate objectives, indicating the company's active engagement in capital markets.
- Offering Arrangement: The offering is being managed solely by ThinkEquity and is expected to close on June 2, 2026, reflecting the company's strategic planning in financing aligned with market demand.
- Compliance Assurance: The company is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, ensuring that the transaction complies with relevant regulations, which enhances investor confidence in the company's compliance.
- Future Outlook: BriaCell intends to use the proceeds to advance its cancer immunotherapy development, demonstrating the company's commitment to long-term growth and innovation in the biotechnology sector, which may attract more investor interest in its future potential.
See More
BriaCell Reports Promising Phase 2 Data for Breast Cancer Treatment
- Survival Rate Improvement: The Bria-IMT regimen demonstrated a 55% one-year and 27% two-year survival rate in heavily pre-treated metastatic breast cancer patients, indicating significant potential for improving survival, particularly in patients who have failed multiple therapies.
- Clinical Data Validation: At the 2026 ASCO Annual Meeting, BriaCell reported a median overall survival of 16.6 months in Phase 2 studies, with a clinical benefit rate of 62% among patients who had undergone various treatments, underscoring the regimen's efficacy and tolerability.
- Biomarker Insights: Ongoing biomarker analyses from the Phase 3 study further validate potential predictors of anti-cancer response, with DTH-positive patients showing a median survival of 11.9 months, highlighting the importance of biomarkers in predicting treatment effectiveness.
- Quality of Life Enhancement: In the Bria-ABC study, heavily pre-treated patients maintained stable quality of life without significant toxicity, supporting the feasibility of the regimen in clinical settings and suggesting potential for home self-administration.
See More
BriaCell Therapeutics Prices 1.4 Million Share Best-Efforts Offering
- Offering Size: BriaCell Therapeutics announced a best-efforts offering of approximately 1.4 million shares, indicating the company's strategy to raise capital in the market.
- Market Reaction: The specific pricing details of the offering have not been disclosed, which may affect investor confidence in the company's future fundraising capabilities.
- Use of Proceeds: While the use of proceeds has not been detailed, such financing is typically aimed at research and operational expenses, potentially impacting the company's future project timelines.
- Investor Attention: Investors should monitor subsequent market reactions and company announcements to assess the potential impact of this offering on stock price and financial health.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
BriaCell's Immunotherapy Study Receives Positive DSMB Recommendation
- Clinical Trial Progress: BriaCell Therapeutics' Bria-ABC study in metastatic breast cancer has received its sixth consecutive positive recommendation from the independent Data Safety Monitoring Board, indicating no safety concerns and allowing the trial to proceed without modifications.
- FDA Fast Track Designation: Conducted under FDA Fast Track designation, the study underscores the significant unmet medical need in metastatic breast cancer, highlighting the strategic importance of the company's development of novel immunotherapies.
- CEO's Positive Remarks: CEO Dr. William V. Williams described this milestone as 'another step forward,' emphasizing BriaCell's commitment to addressing urgent patient needs and advancing its immunotherapy approach.
- Stock Performance Volatility: BCTX shares have traded between $2.98 and $36.90 over the past year, closing at $3.49, down 6.18% from the previous trading day, reflecting market caution regarding the company's future prospects.
See More
BriaCell's Phase 3 Study Receives Sixth Positive DSMB Recommendation
- Safety Assessment Results: The independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of BriaCell's Phase 3 Bria-ABC study, indicating favorable safety and tolerability of the immunotherapy, which enhances investor confidence in the company's future prospects.
- FDA Fast Track Designation: The study is being conducted under the FDA's Fast Track designation, reflecting a significant unmet medical need in metastatic breast cancer, positioning BriaCell's innovative therapies to potentially fill this market gap and enhance the company's competitiveness in the biotechnology sector.
- Clinical Trial Progress: The positive DSMB recommendation suggests that the combination of Bria-IMT and immune checkpoint inhibitors shows good safety in clinical trials, potentially offering new hope for patients in urgent need of treatment, thereby increasing BriaCell's market recognition.
- Strategic Company Implications: BriaCell's CEO, William V. Williams, noted that this milestone not only recognizes the company's research capabilities but also lays the groundwork for future financing and collaboration opportunities, further driving innovation in cancer treatment.
See More
